Palforzia for treating peanut allergy in children and young people (TA769)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Cryotherapy for Chronic RhinitisStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: 27 September 2023
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites (ID1278)Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 26 June 2024
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (ID3961)Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID 5093]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over [ID 5107]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 TS ID 10510Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC